Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 80 entries
Sorted by: Best Match Show Resources per page
Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration.

Frontiers in human neuroscience

Di Lorenzo G, Daverio A, Ferrentino F, Santarnecchi E, Ciabattini F, Monaco L, Lisi G, Barone Y, Di Lorenzo C, Niolu C, Seri S, Siracusano A.
PMID: 25999835
Front Hum Neurosci. 2015 May 05;9:234. doi: 10.3389/fnhum.2015.00234. eCollection 2015.

Despite the increasing body of evidence supporting the hypothesis of schizophrenia as a disconnection syndrome, studies of resting-state EEG Source Functional Connectivity (EEG-SFC) in people affected by schizophrenia are sparse. The aim of the present study was to investigate...

Cite
Di Lorenzo G, Daverio A, Ferrentino F, et al. Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration. Front Hum Neurosci. 2015;9:234doi: 10.3389/fnhum.2015.00234.
Di Lorenzo, G., Daverio, A., Ferrentino, F., Santarnecchi, E., Ciabattini, F., Monaco, L., Lisi, G., Barone, Y., Di Lorenzo, C., Niolu, C., Seri, S., & Siracusano, A. (2015). Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration. Frontiers in human neuroscience, 9234. https://doi.org/10.3389/fnhum.2015.00234
Di Lorenzo, Giorgio, et al. "Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration." Frontiers in human neuroscience vol. 9 (2015): 234. doi: https://doi.org/10.3389/fnhum.2015.00234
Di Lorenzo G, Daverio A, Ferrentino F, Santarnecchi E, Ciabattini F, Monaco L, Lisi G, Barone Y, Di Lorenzo C, Niolu C, Seri S, Siracusano A. Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration. Front Hum Neurosci. 2015 May 05;9:234. doi: 10.3389/fnhum.2015.00234. eCollection 2015. PMID: 25999835; PMCID: PMC4419718.
Copy Download .nbib Format: NLM
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib.

Oncotarget

Breccia M, Molica M, Colafigli G, Massaro F, Quattrocchi L, Latagliata R, Mancini M, Diverio D, Guarini A, Alimena G, Foà R.
PMID: 29484130
Oncotarget. 2017 Dec 26;9(7):7534-7540. doi: 10.18632/oncotarget.23691. eCollection 2018 Jan 26.

Deep molecular response in chronic myeloid leukemia (CML) patients treated with imatinib is a prerequisite for possible discontinuation. We identify clinico-biologic features linked with the probability of reaching MR4.5 (BCR-ABL/ABL ≤ 0.0032% IS) as a stable response (confirmed on...

Cite
Breccia M, Molica M, Colafigli G, et al. Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. Oncotarget. 2017;9(7):7534-7540doi: 10.18632/oncotarget.23691.
Breccia, M., Molica, M., Colafigli, G., Massaro, F., Quattrocchi, L., Latagliata, R., Mancini, M., Diverio, D., Guarini, A., Alimena, G., & Foà, R. (2018). Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. Oncotarget, 9(7), 7534-7540. https://doi.org/10.18632/oncotarget.23691
Breccia, Massimo, et al. "Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib." Oncotarget vol. 9,7 (2018): 7534-7540. doi: https://doi.org/10.18632/oncotarget.23691
Breccia M, Molica M, Colafigli G, Massaro F, Quattrocchi L, Latagliata R, Mancini M, Diverio D, Guarini A, Alimena G, Foà R. Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. Oncotarget. 2017 Dec 26;9(7):7534-7540. doi: 10.18632/oncotarget.23691. eCollection 2018 Jan 26. PMID: 29484130; PMCID: PMC5800922.
Copy Download .nbib Format: NLM
Structural Substituent Effect in the Excitation Energy of a Chromophore: Quantitative Determination and Application to S-Nitrosothiols.

Journal of chemical theory and computation

Fernández-González MÁ, Marazzi M, López-Delgado A, Zapata F, García-Iriepa C, Rivero D, Castaño O, Temprado M, Frutos LM.
PMID: 26605736
J Chem Theory Comput. 2012 Sep 11;8(9):3293-302. doi: 10.1021/ct300597u. Epub 2012 Aug 29.

A methodology for the prediction of excitation energies for substituted chromophores on the basis of ground state structures has been developed. The formalism introduces the concept of "structural substituent excitation energy effect" for the rational prediction and quantification of...

Cite
Fernández-González MÁ, Marazzi M, López-Delgado A, et al. Structural Substituent Effect in the Excitation Energy of a Chromophore: Quantitative Determination and Application to S-Nitrosothiols. J Chem Theory Comput. 2012;8(9):3293-302doi: 10.1021/ct300597u.
Fernández-González, M. �. �., Marazzi, M., López-Delgado, A., Zapata, F., García-Iriepa, C., Rivero, D., Castaño, O., Temprado, M., & Frutos, L. M. (2012). Structural Substituent Effect in the Excitation Energy of a Chromophore: Quantitative Determination and Application to S-Nitrosothiols. Journal of chemical theory and computation, 8(9), 3293-302. https://doi.org/10.1021/ct300597u
Fernández-González, Miguel Ángel, et al. "Structural Substituent Effect in the Excitation Energy of a Chromophore: Quantitative Determination and Application to S-Nitrosothiols." Journal of chemical theory and computation vol. 8,9 (2012): 3293-302. doi: https://doi.org/10.1021/ct300597u
Fernández-González MÁ, Marazzi M, López-Delgado A, Zapata F, García-Iriepa C, Rivero D, Castaño O, Temprado M, Frutos LM. Structural Substituent Effect in the Excitation Energy of a Chromophore: Quantitative Determination and Application to S-Nitrosothiols. J Chem Theory Comput. 2012 Sep 11;8(9):3293-302. doi: 10.1021/ct300597u. Epub 2012 Aug 29. PMID: 26605736.
Copy Download .nbib Format: NLM
Spontaneous subdural hematoma of the thoracolumbar region with massive recurrent bleed.

Indian journal of orthopaedics

Cincu R, de Asis Lorente F, Rivero D, Eiras J, Ara JR.
PMID: 19838395
Indian J Orthop. 2009 Oct;43(4):412-5. doi: 10.4103/0019-5413.49383.

Spinal subdural hematoma is a rare disorder and can be caused by abnormalities of coagulation, blood dyscrasias, lumbar puncture, trauma, underlying neoplasm, and arteriovenous malformation. We discuss an unusual case of an elderly woman who presented with spontaneous spinal...

Cite
Cincu R, de Asis Lorente F, Rivero D, et al. Spontaneous subdural hematoma of the thoracolumbar region with massive recurrent bleed. Indian J Orthop. 2009;43(4):412-5doi: 10.4103/0019-5413.49383.
Cincu, R., de Asis Lorente, F., Rivero, D., Eiras, J., & Ara, J. R. (2009). Spontaneous subdural hematoma of the thoracolumbar region with massive recurrent bleed. Indian journal of orthopaedics, 43(4), 412-5. https://doi.org/10.4103/0019-5413.49383
Cincu, Rafael, et al. "Spontaneous subdural hematoma of the thoracolumbar region with massive recurrent bleed." Indian journal of orthopaedics vol. 43,4 (2009): 412-5. doi: https://doi.org/10.4103/0019-5413.49383
Cincu R, de Asis Lorente F, Rivero D, Eiras J, Ara JR. Spontaneous subdural hematoma of the thoracolumbar region with massive recurrent bleed. Indian J Orthop. 2009 Oct;43(4):412-5. doi: 10.4103/0019-5413.49383. PMID: 19838395; PMCID: PMC2762564.
Copy Download .nbib Format: NLM
Effect of subtalar joint position on the measurement of maximum ankle dorsiflexic.

Clinical biomechanics (Bristol, Avon)

Tiberio D, Bohannon RW, Zito MA.
PMID: 23916041
Clin Biomech (Bristol, Avon). 1989 Aug;4(3):189-91. doi: 10.1016/0268-0033(89)90024-7.

Measurements of maximum ankle dorsiflexion (MAD) are frequently performed in clinical practice, yet no single technique has gained universal acceptance. The purpose of this study was to determine whether a significant difference exists in passive MAD measurement with the...

Cite
Tiberio D, Bohannon RW, Zito MA. Effect of subtalar joint position on the measurement of maximum ankle dorsiflexic. Clin Biomech (Bristol, Avon). 1989;4(3):189-91doi: 10.1016/0268-0033(89)90024-7.
Tiberio, D., Bohannon, R. W., & Zito, M. A. (1989). Effect of subtalar joint position on the measurement of maximum ankle dorsiflexic. Clinical biomechanics (Bristol, Avon), 4(3), 189-91. https://doi.org/10.1016/0268-0033(89)90024-7
Tiberio, D, et al. "Effect of subtalar joint position on the measurement of maximum ankle dorsiflexic." Clinical biomechanics (Bristol, Avon) vol. 4,3 (1989): 189-91. doi: https://doi.org/10.1016/0268-0033(89)90024-7
Tiberio D, Bohannon RW, Zito MA. Effect of subtalar joint position on the measurement of maximum ankle dorsiflexic. Clin Biomech (Bristol, Avon). 1989 Aug;4(3):189-91. doi: 10.1016/0268-0033(89)90024-7. PMID: 23916041.
Copy Download .nbib Format: NLM
DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells.

Immunome research

Cavalieri D, Rivero D, Beltrame L, Buschow SI, Calura E, Rizzetto L, Gessani S, Gauzzi MC, Reith W, Baur A, Bonaiuti R, Brandizi M, De Filippo C, D'Oro U, Draghici S, Dunand-Sauthier I, Gatti E, Granucci F, Gündel M, Kramer M, Kuka M, Lanyi A, Melief CJ, van Montfoort N, Ostuni R, Pierre P, Popovici R, Rajnavolgyi E, Schierer S, Schuler G, Soumelis V, Splendiani A, Stefanini I, Torcia MG, Zanoni I, Zollinger R, Figdor CG, Austyn JM.
PMID: 21092113
Immunome Res. 2010 Nov 19;6:10. doi: 10.1186/1745-7580-6-10.

BACKGROUND: The advent of Systems Biology has been accompanied by the blooming of pathway databases. Currently pathways are defined generically with respect to the organ or cell type where a reaction takes place. The cell type specificity of the...

Cite
Cavalieri D, Rivero D, Beltrame L, et al. DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells. Immunome Res. 2010;6:10doi: 10.1186/1745-7580-6-10.
Cavalieri, D., Rivero, D., Beltrame, L., Buschow, S. I., Calura, E., Rizzetto, L., Gessani, S., Gauzzi, M. C., Reith, W., Baur, A., Bonaiuti, R., Brandizi, M., De Filippo, C., D'Oro, U., Draghici, S., Dunand-Sauthier, I., Gatti, E., Granucci, F., Gündel, M., Kramer, M., Kuka, M., Lanyi, A., Melief, C. J., van Montfoort, N., Ostuni, R., Pierre, P., Popovici, R., Rajnavolgyi, E., Schierer, S., Schuler, G., Soumelis, V., Splendiani, A., Stefanini, I., Torcia, M. G., Zanoni, I., Zollinger, R., Figdor, C. G., & Austyn, J. M. (2010). DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells. Immunome research, 610. https://doi.org/10.1186/1745-7580-6-10
Cavalieri, Duccio, et al. "DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells." Immunome research vol. 6 (2010): 10. doi: https://doi.org/10.1186/1745-7580-6-10
Cavalieri D, Rivero D, Beltrame L, Buschow SI, Calura E, Rizzetto L, Gessani S, Gauzzi MC, Reith W, Baur A, Bonaiuti R, Brandizi M, De Filippo C, D'Oro U, Draghici S, Dunand-Sauthier I, Gatti E, Granucci F, Gündel M, Kramer M, Kuka M, Lanyi A, Melief CJ, van Montfoort N, Ostuni R, Pierre P, Popovici R, Rajnavolgyi E, Schierer S, Schuler G, Soumelis V, Splendiani A, Stefanini I, Torcia MG, Zanoni I, Zollinger R, Figdor CG, Austyn JM. DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells. Immunome Res. 2010 Nov 19;6:10. doi: 10.1186/1745-7580-6-10. PMID: 21092113; PMCID: PMC3000836.
Copy Download .nbib Format: NLM
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?.

European journal of haematology

Latagliata R, Breccia M, Carmosino I, Cesini L, De Benedittis D, Mohamed S, Vozella F, Molica M, Campanelli M, De Luca ML, Colafigli G, Quattrocchi L, Loglisci MG, Massaro F, Canichella M, Diverio D, Mancini M, Alimena G, Foà R.
PMID: 29896890
Eur J Haematol. 2018 Jun 13; doi: 10.1111/ejh.13110. Epub 2018 Jun 13.

OBJECTIVES: To evaluate differences in clinical results according to age among patients with chronic myeloid leukemia (CML).METHODS: 207 consecutive CML patients treated with imatinib frontline were revised, dividing them in young adults (>20 

Cite
Latagliata R, Breccia M, Carmosino I, et al. Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. Eur J Haematol. 2018;doi: 10.1111/ejh.13110.
Latagliata, R., Breccia, M., Carmosino, I., Cesini, L., De Benedittis, D., Mohamed, S., Vozella, F., Molica, M., Campanelli, M., De Luca, M. L., Colafigli, G., Quattrocchi, L., Loglisci, M. G., Massaro, F., Canichella, M., Diverio, D., Mancini, M., Alimena, G., & Foà, R. (2018). Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. European journal of haematology, . https://doi.org/10.1111/ejh.13110
Latagliata, Roberto, et al. "Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?." European journal of haematology vol. (2018). doi: https://doi.org/10.1111/ejh.13110
Latagliata R, Breccia M, Carmosino I, Cesini L, De Benedittis D, Mohamed S, Vozella F, Molica M, Campanelli M, De Luca ML, Colafigli G, Quattrocchi L, Loglisci MG, Massaro F, Canichella M, Diverio D, Mancini M, Alimena G, Foà R. Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. Eur J Haematol. 2018 Jun 13; doi: 10.1111/ejh.13110. Epub 2018 Jun 13. PMID: 29896890.
Copy Download .nbib Format: NLM
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus.

Annals of translational medicine

Kosmas CE, Sourlas A, Bouza KV, DeJesus E, Silverio D, Montan PD, Guzman E.
PMID: 29955590
Ann Transl Med. 2018 Apr;6(7):130. doi: 10.21037/atm.2018.02.20.

No abstract available.

Cite
Kosmas CE, Sourlas A, Bouza KV, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus. Ann Transl Med. 2018;6(7):130doi: 10.21037/atm.2018.02.20.
Kosmas, C. E., Sourlas, A., Bouza, K. V., DeJesus, E., Silverio, D., Montan, P. D., & Guzman, E. (2018). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus. Annals of translational medicine, 6(7), 130. https://doi.org/10.21037/atm.2018.02.20
Kosmas, Constantine E, et al. "Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus." Annals of translational medicine vol. 6,7 (2018): 130. doi: https://doi.org/10.21037/atm.2018.02.20
Kosmas CE, Sourlas A, Bouza KV, DeJesus E, Silverio D, Montan PD, Guzman E. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus. Ann Transl Med. 2018 Apr;6(7):130. doi: 10.21037/atm.2018.02.20. PMID: 29955590; PMCID: PMC6015935.
Copy Download .nbib Format: NLM
'Candidatus Liberibacter solanacearum' Associated with Bactericera trigonica-Affected Carrots in the Canary Islands.

Plant disease

Alfaro-Fernández A, Siverio F, Cebrián MC, Villaescusa FJ, Font MI.
PMID: 30727402
Plant Dis. 2012 Apr;96(4):581. doi: 10.1094/PDIS-10-11-0878-PDN.

In 2009 and 2010, commercial carrot (Daucus carota L.) fields located in Tenerife (Canary Islands, Spain) showed symptoms of curling, yellow, bronze, and purple discoloration of leaves, stunting of shoots and tap roots, and proliferation of secondary roots. A...

Cite
Alfaro-Fernández A, Siverio F, Cebrián MC, et al. 'Candidatus Liberibacter solanacearum' Associated with Bactericera trigonica-Affected Carrots in the Canary Islands. Plant Dis. 2012;96(4):581doi: 10.1094/PDIS-10-11-0878-PDN.
Alfaro-Fernández, A., Siverio, F., Cebrián, M. C., Villaescusa, F. J., & Font, M. I. (2012). 'Candidatus Liberibacter solanacearum' Associated with Bactericera trigonica-Affected Carrots in the Canary Islands. Plant disease, 96(4), 581. https://doi.org/10.1094/PDIS-10-11-0878-PDN
Alfaro-Fernández, A, et al. "'Candidatus Liberibacter solanacearum' Associated with Bactericera trigonica-Affected Carrots in the Canary Islands." Plant disease vol. 96,4 (2012): 581. doi: https://doi.org/10.1094/PDIS-10-11-0878-PDN
Alfaro-Fernández A, Siverio F, Cebrián MC, Villaescusa FJ, Font MI. 'Candidatus Liberibacter solanacearum' Associated with Bactericera trigonica-Affected Carrots in the Canary Islands. Plant Dis. 2012 Apr;96(4):581. doi: 10.1094/PDIS-10-11-0878-PDN. PMID: 30727402.
Copy Download .nbib Format: NLM
Role of spironolactone in the treatment of heart failure with preserved ejection fraction.

Annals of translational medicine

Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E.
PMID: 30603649
Ann Transl Med. 2018 Dec;6(23):461. doi: 10.21037/atm.2018.11.16.

Heart failure (HF) is the leading cause of morbidity and mortality globally. Heart failure with preserved ejection fraction (HFpEF) is currently responsible for about half of the patients affected with HF and is associated with impaired functional capacity, as...

Cite
Kosmas CE, Silverio D, Sourlas A, et al. Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Ann Transl Med. 2018;6(23):461doi: 10.21037/atm.2018.11.16.
Kosmas, C. E., Silverio, D., Sourlas, A., Montan, P. D., & Guzman, E. (2018). Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Annals of translational medicine, 6(23), 461. https://doi.org/10.21037/atm.2018.11.16
Kosmas, Constantine E, et al. "Role of spironolactone in the treatment of heart failure with preserved ejection fraction." Annals of translational medicine vol. 6,23 (2018): 461. doi: https://doi.org/10.21037/atm.2018.11.16
Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E. Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Ann Transl Med. 2018 Dec;6(23):461. doi: 10.21037/atm.2018.11.16. PMID: 30603649; PMCID: PMC6312809.
Copy Download .nbib Format: NLM
Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19.

Kidney international reports

Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ, Cacho J, Cabello Pelegrin S, Melilli E, Aladrén MJ, Galeano C, Lorenzo I, Mazuecos A, Saura IM, Franco A, Ruiz-Fuentes MDC, Sánchez-Cámara LA, Siverio O, Martin ML, González-García E, López V, Martin-Moreno PL, Moina I, Moral Berrio E, Moreso F, Portolés JM, Santana-Estupiñán R, Zárraga S, Canal C, Sánchez-Álvarez E, Pascual J, Crespo M.
PMID: 34250317
Kidney Int Rep. 2021 Sep;6(9):2305-2315. doi: 10.1016/j.ekir.2021.06.023. Epub 2021 Jul 06.

INTRODUCTION: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety...

Cite
Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ, et al. Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. Kidney Int Rep. 2021;6(9):2305-2315doi: 10.1016/j.ekir.2021.06.023.
Buxeda, A., Arias-Cabrales, C., Pérez-Sáez, M. J., Cacho, J., Cabello Pelegrin, S., Melilli, E., Aladrén, M. J., Galeano, C., Lorenzo, I., Mazuecos, A., Saura, I. M., Franco, A., Ruiz-Fuentes, M. D. C., Sánchez-Cámara, L. A., Siverio, O., Martin, M. L., González-García, E., López, V., Martin-Moreno, P. L., Moina, I., Moral Berrio, E., Moreso, F., Portolés, J. M., Santana-Estupiñán, R., Zárraga, S., Canal, C., Sánchez-Álvarez, E., Pascual, J., & Crespo, M. (2021). Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. Kidney international reports, 6(9), 2305-2315. https://doi.org/10.1016/j.ekir.2021.06.023
Buxeda, Anna, et al. "Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19." Kidney international reports vol. 6,9 (2021): 2305-2315. doi: https://doi.org/10.1016/j.ekir.2021.06.023
Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ, Cacho J, Cabello Pelegrin S, Melilli E, Aladrén MJ, Galeano C, Lorenzo I, Mazuecos A, Saura IM, Franco A, Ruiz-Fuentes MDC, Sánchez-Cámara LA, Siverio O, Martin ML, González-García E, López V, Martin-Moreno PL, Moina I, Moral Berrio E, Moreso F, Portolés JM, Santana-Estupiñán R, Zárraga S, Canal C, Sánchez-Álvarez E, Pascual J, Crespo M. Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. Kidney Int Rep. 2021 Sep;6(9):2305-2315. doi: 10.1016/j.ekir.2021.06.023. Epub 2021 Jul 06. PMID: 34250317; PMCID: PMC8257403.
Copy Download .nbib Format: NLM
Correction to: Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review.

Antimicrobial resistance and infection control

Donà D, Barbieri E, Daverio M, Lundin R, Giaquinto C, Zaoutis T, Sharland M.
PMID: 32381059
Antimicrob Resist Infect Control. 2020 May 07;9(1):59. doi: 10.1186/s13756-020-00720-x.

The original article [1] contains an error in Fig. 1 whereby the number of selected articles of the first box is incorrect.

Cite
Donà D, Barbieri E, Daverio M, et al. Correction to: Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review. Antimicrob Resist Infect Control. 2020;9(1):59doi: 10.1186/s13756-020-00720-x.
Donà, D., Barbieri, E., Daverio, M., Lundin, R., Giaquinto, C., Zaoutis, T., & Sharland, M. (2020). Correction to: Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review. Antimicrobial resistance and infection control, 9(1), 59. https://doi.org/10.1186/s13756-020-00720-x
Donà, D, et al. "Correction to: Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review." Antimicrobial resistance and infection control vol. 9,1 (2020): 59. doi: https://doi.org/10.1186/s13756-020-00720-x
Donà D, Barbieri E, Daverio M, Lundin R, Giaquinto C, Zaoutis T, Sharland M. Correction to: Implementation and impact of pediatric antimicrobial stewardship programs: a systematic scoping review. Antimicrob Resist Infect Control. 2020 May 07;9(1):59. doi: 10.1186/s13756-020-00720-x. PMID: 32381059; PMCID: PMC7206826.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 80 entries